CoChat

Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The ability to properly model intravascular steps in metastasis is essential in identifying key physical, cellular, and molecular determinants that can be targeted therapeutically to prevent metastatic disease. Research on the vascular microenvironment has been hindered by challenges in studying this compartment in metastasis under conditions that reproduce in vivo physiology while allowing facile experimental manipulation. METHODOLOGY/PRINCIPAL FINDINGS: We present a microfluidic vasculature system to model interactions between circulating breast cancer cells with microvascular endothelium at potential sites of metastasis. The microfluidic vasculature produces spatially-restricted stimulation from the basal side of the endothelium that models both organ-specific localization and polarization of chemokines and many other signaling molecules under variable flow conditions. We used this microfluidic system to produce site-specific stimulation of microvascular endothelium with CXCL12, a chemokine strongly implicated in metastasis. CONCLUSIONS/SIGNIFICANCE: When added from the basal side, CXCL12 acts through receptor CXCR4 on endothelium to promote adhesion of circulating breast cancer cells, independent of CXCL12 receptors CXCR4 or CXCR7 on tumor cells. These studies suggest that targeting CXCL12-CXCR4 signaling in endothelium may limit metastases in breast and other cancers and highlight the unique capabilities of our microfluidic device to advance studies of the intravascular microenvironment in metastasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0005756

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Microfluidic vasculature enables region-specific activation of endothelium under physiological flow conditions. (A) Schematic of the poly(dimethysiloxane) (PDMS) microfluidic device demonstrating multi-layer fabrication with a thin, porous polyester membrane sandwiched by the top and bottom PDMS layers. (B) Chemokine in the bottom channel activates the endothelium from the basal face while cancer cells flow in the top channel above the endothelium. (C) Phase contrast image of HDMECs cultured in the microfluidic device. The image depicts the entire length of the endothelium with the upstream, middle, and downstream regions clearly demarcated from each other. Scale bar represents 800 µm. (D) Photograph of the microfluidic device loaded with blue dye in the top channel and red dye in the two bottom channels. (E) Top view of the microfluidic device. Fluid flows away from the funnel-shaped inlet and through the top channel. (F) Validation of region-specific stimulation of endothelium. The upstream and downstream lower channels were filled with Syto 64, a fluorescent dye that stains cells. HDMECs overlying the upstream and downstream bottom channels, but not HDMECs in the middle of the channel fluoresce. Fluorescence was evident within 15 minutes, remained spatially-restricted for at least 5.5 hours, and persisted after 30 minutes of flow through the top channel. Image shows the 5.5 hour point after initial treatment. Scale bar represents 800 µm. (G) Representative fluorescent images of adhesion of 231-control cells (stably expressing GFP) onto region-specific TNF-α treated endothelium under 0.50 dyn cm−2 shear stress flow conditions. In these images, the downstream region was treated with TNF-α for 5 h (denoted by a ‘+’) while the upstream and middle regions were left untreated. Scale bar represents 200 µm.
Figure 1 Microfluidic vasculature enables region-specific activation of endothelium under physiological flow conditions. (A) Schematic of the poly(dimethysiloxane) (PDMS) microfluidic device demonstrating multi-layer fabrication with a thin, porous polyester membrane sandwiched by the top and bottom PDMS layers. (B) Chemokine in the bottom channel activates the endothelium from the basal face while cancer cells flow in the top channel above the endothelium. (C) Phase contrast image of HDMECs cultured in the microfluidic device. The image depicts the entire length of the endothelium with the upstream, middle, and downstream regions clearly demarcated from each other. Scale bar represents 800 µm. (D) Photograph of the microfluidic device loaded with blue dye in the top channel and red dye in the two bottom channels. (E) Top view of the microfluidic device. Fluid flows away from the funnel-shaped inlet and through the top channel. (F) Validation of region-specific stimulation of endothelium. The upstream and downstream lower channels were filled with Syto 64, a fluorescent dye that stains cells. HDMECs overlying the upstream and downstream bottom channels, but not HDMECs in the middle of the channel fluoresce. Fluorescence was evident within 15 minutes, remained spatially-restricted for at least 5.5 hours, and persisted after 30 minutes of flow through the top channel. Image shows the 5.5 hour point after initial treatment. Scale bar represents 800 µm. (G) Representative fluorescent images of adhesion of 231-control cells (stably expressing GFP) onto region-specific TNF-α treated endothelium under 0.50 dyn cm−2 shear stress flow conditions. In these images, the downstream region was treated with TNF-α for 5 h (denoted by a ‘+’) while the upstream and middle regions were left untreated. Scale bar represents 200 µm.CC BY · PubMed Central
Figure 2 Enhanced binding of CXCL12 presented to the basal versus apical surface of endothelium mediates increased adhesion of cancer cells. (A) HDMEC cells 2 cultured on transwell inserts were incubated with ≈ 40 ng ml−1 CXCL12-GL added to either the top (apical) or bottom (basal) compartment for 5 hours. Control wells were incubated with equal amount of unfused GL (based on ioluminescence) added to either the top or bottom compartment. Cell-associated luciferase activity from CXCL12-GL or GL was quantified by bioluminescence imaging. Data are mean values combined from two independent experiments (n = 4, 5 for each condition). Inset shows representative bioluminescence images of CXCL12-GL associated with endothelial cells. Images are presented as a pseudocolor display with red and blue depicting the highest and lowest levels of photons, respectively. Note, 40 ng ml−1 is the highest concentration of CXCL12-GL that we can collect. (b) HDMECs in transwells were treated with 100 ng ml−1 CXCL12 either apically or basally. Following incubation with 231-control cancer cells and subsequent washing to remove non-adherent cells, approximately twice as many cancer cells remain adhered onto endothelium treated with CXCL12 basally versus apically. The fraction of cells that remain adhered was calculated from the number of cancer cells added into empty wells from the same cell suspension. n = 36 for each condition. *, p<0.05.
Figure 2 Enhanced binding of CXCL12 presented to the basal versus apical surface of endothelium mediates increased adhesion of cancer cells. (A) HDMEC cells 2 cultured on transwell inserts were incubated with ≈ 40 ng ml−1 CXCL12-GL added to either the top (apical) or bottom (basal) compartment for 5 hours. Control wells were incubated with equal amount of unfused GL (based on ioluminescence) added to either the top or bottom compartment. Cell-associated luciferase activity from CXCL12-GL or GL was quantified by bioluminescence imaging. Data are mean values combined from two independent experiments (n = 4, 5 for each condition). Inset shows representative bioluminescence images of CXCL12-GL associated with endothelial cells. Images are presented as a pseudocolor display with red and blue depicting the highest and lowest levels of photons, respectively. Note, 40 ng ml−1 is the highest concentration of CXCL12-GL that we can collect. (b) HDMECs in transwells were treated with 100 ng ml−1 CXCL12 either apically or basally. Following incubation with 231-control cancer cells and subsequent washing to remove non-adherent cells, approximately twice as many cancer cells remain adhered onto endothelium treated with CXCL12 basally versus apically. The fraction of cells that remain adhered was calculated from the number of cancer cells added into empty wells from the same cell suspension. n = 36 for each condition. *, p<0.05.CC BY · PubMed Central
Figure 3 Endothelial cells mediate CXCL12-dependent enhancement in adhesion of cancer cells. (A) Flow cytometry with antibodies to CXCR4 (12G5) or CXCR7 (11G8) shows expression in stably transduced cell lines and absence of these receptors in 231-control cells. Filled histogram, isotype antibody control; open histogram, antibody stain. Isotype control staining overlapped with unstained cells (not shown on the plots). (B) CXCL12-dependent activation of AKT in 231 cells determined by Western Blot. Breast cancer cell lines were cultured overnight in medium containing 0.5% serum and then treated with 100 ng ml−1 CXCL12 for 3 min, 10 min, or no CXCL12 (NT). Cell lysates were probed for phosphorylation of AKT at serine 473. Blots then were stripped and probed for total AKT as a loading control. Similar results were obtained with 300 ng ml−1 and incubations extending through 30 minutes. (C) Adhesion of 231-CXCR4, 231-CXCR7, and 231-control cancer cells onto CXCL12 treated versus untreated endothelium under 0.50 dyn cm−2 shear flow conditions. For all three cancer cell-types, adhesion selectivity was towards the CXCL12 treated region of the endothelium over the corresponding untreated region (*). The level of adhesion of the three different cancer cell-types was statistically different on both the CXCL12 treated and untreated endothelial regions (**). Data are expressed as mean+s.e.m. (D) Adhesion selectivity of cancer cells towards the CXCL12 treated endothelial region over the untreated region under 0.50 dyn cm−2 flow conditions. Adhesion selectivity to CXCL12-stimulated endothelium was comparable for all cancer cell lines, regardless of expression of CXCR4 or CXCR7. #, p = 0.48. Statistical significance as determined by Mann-Whitney (*, p<0.05) for pair wise comparison and Kruskal-Wallis (**, p<0.05) for comparison of more than two groups.
Figure 3 Endothelial cells mediate CXCL12-dependent enhancement in adhesion of cancer cells. (A) Flow cytometry with antibodies to CXCR4 (12G5) or CXCR7 (11G8) shows expression in stably transduced cell lines and absence of these receptors in 231-control cells. Filled histogram, isotype antibody control; open histogram, antibody stain. Isotype control staining overlapped with unstained cells (not shown on the plots). (B) CXCL12-dependent activation of AKT in 231 cells determined by Western Blot. Breast cancer cell lines were cultured overnight in medium containing 0.5% serum and then treated with 100 ng ml−1 CXCL12 for 3 min, 10 min, or no CXCL12 (NT). Cell lysates were probed for phosphorylation of AKT at serine 473. Blots then were stripped and probed for total AKT as a loading control. Similar results were obtained with 300 ng ml−1 and incubations extending through 30 minutes. (C) Adhesion of 231-CXCR4, 231-CXCR7, and 231-control cancer cells onto CXCL12 treated versus untreated endothelium under 0.50 dyn cm−2 shear flow conditions. For all three cancer cell-types, adhesion selectivity was towards the CXCL12 treated region of the endothelium over the corresponding untreated region (*). The level of adhesion of the three different cancer cell-types was statistically different on both the CXCL12 treated and untreated endothelial regions (**). Data are expressed as mean+s.e.m. (D) Adhesion selectivity of cancer cells towards the CXCL12 treated endothelial region over the untreated region under 0.50 dyn cm−2 flow conditions. Adhesion selectivity to CXCL12-stimulated endothelium was comparable for all cancer cell lines, regardless of expression of CXCR4 or CXCR7. #, p = 0.48. Statistical significance as determined by Mann-Whitney (*, p<0.05) for pair wise comparison and Kruskal-Wallis (**, p<0.05) for comparison of more than two groups.CC BY · PubMed Central
Figure 4 Adhesion selectivity of cancer cells onto the CXCL12 treated endothelial region over the untreated region at different flow conditions. The boxplots were grouped together by cancer cell type at 0 (or static), 0.50, and 2.50 dyn cm−2 flow conditions. For each cell type, the adhesion selectivity was statistically different for the different flow conditions (**, p<0.05) with the selectivity consistently increasing from static to flow conditions. n = 4–6 for each condition.
Figure 4 Adhesion selectivity of cancer cells onto the CXCL12 treated endothelial region over the untreated region at different flow conditions. The boxplots were grouped together by cancer cell type at 0 (or static), 0.50, and 2.50 dyn cm−2 flow conditions. For each cell type, the adhesion selectivity was statistically different for the different flow conditions (**, p<0.05) with the selectivity consistently increasing from static to flow conditions. n = 4–6 for each condition.CC BY · PubMed Central
Figure 5 Characterization of CXCL12-mediated response in HDMECs. (A) Chemokine receptor expression in HDMECs determined by reverse transcription PCR (RT-PCR). HDMECs show expression of CXCR4 but not CXCR7 under basal conditions. CXCR4 on HDMECs is upregulated compared to basal conditions by CXCL12 and TNF-α. CXCR7 is upregulated by TNF-α only. RT-PCR for the housekeeping gene GAPDH confirms equivalent loading and intact RNA for all samples. (B) CXCL12 activates AKT in HDMECs as determined by Western Blot. There is CXCL12-dependent activation of AKT that remains greater than control endothelium through 5 hours.
Figure 5 Characterization of CXCL12-mediated response in HDMECs. (A) Chemokine receptor expression in HDMECs determined by reverse transcription PCR (RT-PCR). HDMECs show expression of CXCR4 but not CXCR7 under basal conditions. CXCR4 on HDMECs is upregulated compared to basal conditions by CXCL12 and TNF-α. CXCR7 is upregulated by TNF-α only. RT-PCR for the housekeeping gene GAPDH confirms equivalent loading and intact RNA for all samples. (B) CXCL12 activates AKT in HDMECs as determined by Western Blot. There is CXCL12-dependent activation of AKT that remains greater than control endothelium through 5 hours.CC BY · PubMed Central
Figure 6 Endothelial-CXCR4 dependent adhesion of cancer cells. (A) Adhesion selectivity of 231-control cancer cells towards regions of the endothelium treated with different combinations of CXCL12, TNF-α and the CXCR4 inhibitor AMD3100 for 5 hours under 0.50 dyn cm−2 flow conditions (*). The levels of adhesion onto the differently treated regions were statistically different (**). AMD3100 in the presence of CXCL12 decreased adhesion by 34% relative to the CXCL12 only condition (*). AMD3100 in the presence of CXCL12 and TNF-α decreased adhesion 42% relative to CXCL12+TNF-α (*). The dotted line represents a ratio of 1 or no adhesion selectivity. (B) Same as (A) except the experiments were performed under 2.50 dyn cm−2 flow conditions. n = 4–6 for each condition. (C) Adhesion of 231-control cancer cells is not affected by pre-treatment with chemokine receptor inhibitors. 231-control cells were pre-treated for 5 h with either an inhibitor for CXCR4 (AMD3100) or an anti-CXCR7 antibody (11G8) and compared to no pre-treatment. The level of adhesion was statistically the same for all three conditions onto either CXCL12 treated (5 h) or untreated endothelium (#, p>0.34). For all 231-control cell pre-treatment conditions, the level of adhesion was greater onto CXCL12 treated versus untreated endothelium (*). n = 5–6 for each condition.
Figure 6 Endothelial-CXCR4 dependent adhesion of cancer cells. (A) Adhesion selectivity of 231-control cancer cells towards regions of the endothelium treated with different combinations of CXCL12, TNF-α and the CXCR4 inhibitor AMD3100 for 5 hours under 0.50 dyn cm−2 flow conditions (*). The levels of adhesion onto the differently treated regions were statistically different (**). AMD3100 in the presence of CXCL12 decreased adhesion by 34% relative to the CXCL12 only condition (*). AMD3100 in the presence of CXCL12 and TNF-α decreased adhesion 42% relative to CXCL12+TNF-α (*). The dotted line represents a ratio of 1 or no adhesion selectivity. (B) Same as (A) except the experiments were performed under 2.50 dyn cm−2 flow conditions. n = 4–6 for each condition. (C) Adhesion of 231-control cancer cells is not affected by pre-treatment with chemokine receptor inhibitors. 231-control cells were pre-treated for 5 h with either an inhibitor for CXCR4 (AMD3100) or an anti-CXCR7 antibody (11G8) and compared to no pre-treatment. The level of adhesion was statistically the same for all three conditions onto either CXCL12 treated (5 h) or untreated endothelium (#, p>0.34). For all 231-control cell pre-treatment conditions, the level of adhesion was greater onto CXCL12 treated versus untreated endothelium (*). n = 5–6 for each condition.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 320

Metadata

Authors
Song, J. W., Cavnar, S. P., Walker, A. C., Luker, K. E., Gupta, M., Tung, Y.-C., Luker, G. D., & Takayama, S.
Affiliations
University of Michigan (US)
Corresponding author
  • Luker, Gary D.
  • Takayama, Shuichi
Venue
PLoS ONE
Published
2009-06-01
Volume
4
Issue
6
Pages
e5756
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2057771278
Cited by
317
References
56
Citations by year
2026: 3 · 2025: 7 · 2024: 11 · 2023: 11 · 2022: 12 · 2021: 15 · 2020: 23 · 2019: 25 · 2018: 24 · 2017: 33 · 2016: 18 · 2015: 28 · 2014: 23 · 2013: 30 · 2012: 23
FWCI
8.82
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Susan G. Komen for the Cure
  • Deutscher Akademischer Austauschdienst
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL-084370, R01HL084370)
  • National Cancer Institute (R01CA136829, R01CA136553, P50CA093990)
  • Army Research Office
  • Army Research Laboratory
Topics
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
Keywords
metastatic breast cancer, circulating tumor cells, microvascular endothelium, CXCL12, CXCR4, CXCR7, chemokine signaling, metastasis prevention
MeSH terms
Breast Neoplasms, Cell Adhesion, Cells, Cultured, Humans, Luciferases, Neoplasm Metastasis, Stress, Mechanical, Signal Transduction, Receptors, CXCR4, Reverse Transcriptase Polymerase Chain Reaction, Microfluidics, Cell Line, Tumor, Microfluidic Analytical Techniques, Chemokine CXCL12, Receptors, CXCR

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0005756
The paper
Song, J. W., Cavnar, S. P., Walker, A. C., Luker, K. E., Gupta, M., Tung, Y.-C., Luker, G. D., & Takayama, S. (2009). Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0005756

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.